Todd C. Cozzens net worth and biography

Todd Cozzens Biography and Net Worth

Director of Natera
Todd Cozzens has served as a member of our board of directors since 2011. Mr. Cozzens has been with Sequoia Capital, a venture capital firm, since 2012. From 2010 to 2012, Mr. Cozzens served as Chief Executive Officer of Optum Accountable Care Solutions, a business unit of Optum/United Healthcare Group. From 2000 to 2010, Mr. Cozzens served as Chief Executive Officer of Picis Inc., a provider of electronic medical record software to hospitals, until its acquisition by the UnitedHealth Group in 2010. Mr. Cozzens currently serves on the boards of directors of Health Catalyst, LLC and a number of privately held companies. Mr. Cozzens holds a Bachelor of Arts degree from Marquette University and completed the Program for Management Development at Harvard University.

What is Todd C. Cozzens' net worth?

The estimated net worth of Todd C. Cozzens is at least $1.88 million as of June 11th, 2021. Mr. Cozzens owns 41,640 shares of Natera stock worth more than $1,878,797 as of February 7th. This net worth evaluation does not reflect any other assets that Mr. Cozzens may own. Learn More about Todd C. Cozzens' net worth.

How do I contact Todd C. Cozzens?

The corporate mailing address for Mr. Cozzens and other Natera executives is 201 INDUSTRIAL ROAD SUITE 410, SAN CARLOS CA, 94070. Natera can also be reached via phone at (650) 249-9090 and via email at [email protected] Learn More on Todd C. Cozzens' contact information.

Has Todd C. Cozzens been buying or selling shares of Natera?

Todd C. Cozzens has not been actively trading shares of Natera during the last ninety days. Learn More on Todd C. Cozzens' trading history.

Who are Natera's active insiders?

Natera's insider roster includes Roy Baynes (Director), Roelof Botha (Director), Michael Brophy (CFO), Rowan Chapman (Director), Steven Chapman (CEO), Todd Cozzens (Director), James Healy (Director), Gail Marcus (Director), Daniel Rabinowitz (Insider), Matthew Rabinowitz (Chairman), Herm Rosenman (Director), Robert Schueren (COO), and Jonathan Sheena (Insider). Learn More on Natera's active insiders.

Are insiders buying or selling shares of Natera?

During the last twelve months, Natera insiders bought shares 2 times. They purchased a total of 372,820 shares worth more than $11,323,786.80. During the last twelve months, insiders at the medical research company sold shares 62 times. They sold a total of 164,110 shares worth more than $6,807,068.72. The most recent insider tranaction occured on February, 1st when CFO Michael Burkes Brophy sold 19,326 shares worth more than $844,159.68. Insiders at Natera own 10.3% of the company. Learn More about insider trades at Natera.

Information on this page was last updated on 2/1/2023.

Todd C. Cozzens Insider Trading History at Natera

See Full Table

Todd C. Cozzens Buying and Selling Activity at Natera

This chart shows Todd C. Cozzens's buying and selling at Natera by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Natera Company Overview

Natera logo
Natera, Inc. is a diagnostics company, which engages in the discovery, development, and commercialization of genetic testing services. It provides Panorama non-invasive prenatal test (NIPT), Vistara, horizon carrier screening (HCS), spectrum pre-implantation genetic screening and spectrum pre-implantation genetic diagnosis, Anora products of conception (POC) and non-invasive paternity testing (PAT). The firm also offers Constellation, a cloud-based software product that allows laboratory customers to gain access to the algorithms and bioinformatics in order to validate and launch tests based on the technology. The company was founded by Matthew Rabinowitz and Jonathan Sheena in November 2003 and is headquartered in Austin, TX.
Read More

Today's Range

Now: $45.12
Low: $42.84
High: $45.15

50 Day Range

MA: $40.83
Low: $36.57
High: $46.55

2 Week Range

Now: $45.12
Low: $26.10
High: $74.82

Volume

691,355 shs

Average Volume

1,335,102 shs

Market Capitalization

$4.40 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.26